Influence of afatinib dose on outcomes of advanced EGFR-mutant NSCLC patients with brain metastases (vol 18, 1198, 2018)

被引：3
|
作者：
Tan, Wan-Ling [1 ]
Ng, Quan Sing [1 ]
Lim, Cindy [2 ]
Tan, Eng Huat [1 ]
Toh, Chee Keong [1 ]
Ang, Mei-Kim [1 ]
Kanesvaran, Ravindran [1 ]
Jain, Amit [1 ]
Tan, Daniel S. W. [1 ,3 ]
Lim, Darren Wan-Teck [1 ,4 ]
机构：
[1] Natl Canc Ctr Singapore, Div Med Oncol, Singapore, Singapore
[2] Natl Canc Ctr Singapore, Clin Trials & Epidemiol Sci, Singapore, Singapore
[3] ASTAR, Genome Inst Singapore, Singapore, Singapore
[4] ASTAR, Inst Mol & Cell Biol, Singapore, Singapore
来源：
BMC CANCER | 2018年 / 18卷
关键词：
D O I：
10.1186/s12885-018-5215-7
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
ᅟ
引用
收藏
页数：2
相关论文
共 50 条
  • [41] ERLOTINIB VERSUS RADIATION THERAPY FOR BRAIN METASTASES IN PATIENTS WITH EGFR-MUTANT LUNG ADENOCARCINOMA
    Gerber, Naamit K.
    Yamada, Yoshiya
    Shi, Weiji
    Zhang, Zhigang
    Riely, Gregory
    Beal, Kathryn
    Yu, Helena A.
    Chan, Timothy A.
    Rimner, Andreas
    Wu, Abraham J.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S902 - S902
  • [42] Brain metastases in patients with EGFR-mutant non-small-cell lung cancer
    Rosell, Rafael
    Karachaliou, Niki
    [J]. LANCET RESPIRATORY MEDICINE, 2017, 5 (09): : 669 - 671
  • [43] Outcomes After Combined Modality Therapy for EGFR-Mutant and Wild-Type Locally Advanced NSCLC
    Mak, Raymond H.
    Doran, Elizabeth
    Muzikansky, Alona
    Kang, Josephine
    Neal, Joel W.
    Baldini, Elizabeth H.
    Choi, Noah C.
    Willers, Henning
    Jackman, David M.
    Sequist, Lecia V.
    [J]. ONCOLOGIST, 2011, 16 (06): : 886 - 895
  • [44] Erlotinib Versus Radiation Therapy for Brain Metastases in Patients With EGFR-Mutant Lung Adenocarcinoma
    Gerber, Naamit K.
    Yamada, Yoshiya
    Rimner, Andreas
    Shi, Weiji
    Riely, Gregory J.
    Beal, Kathryn
    Yu, Helena A.
    Chan, Timothy A.
    Zhang, Zhigang
    Wu, Abraham J.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 89 (02): : 322 - 329
  • [45] A Response to the Letter to the Editor: Osimertinib Leads the Way Towards Improving Outcomes of EGFR-Mutant NSCLC With Leptomeningeal Metastases
    Lee, Jiyun
    Ahn, Myung-Ju
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (02) : E14 - E14
  • [46] Antacid and de novo brain metastases in EGFR-mutant NSCLC patients treated with first-line, first-generation EGFR-TKIs
    Chen, Y-M.
    Lin, M-C.
    Lai, C-H.
    Fang, W-F.
    Chang, H-C.
    Wang, C-C.
    Tseng, C-C.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (04) : S132 - S132
  • [47] Successful Salvage Therapy Using High Dose Aumolertinib in T790M-negative EGFR-mutant NSCLC With Brain and Leptomeningeal Metastases
    Li, Y. -B.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S663 - S664
  • [48] Frequency of brain metastases and outcomes in patients with HER2-, KRAS-, and EGFR-mutant lung cancers.
    Kris, Mark G.
    Offin, Michael David
    Feldman, Daniel L.
    Ni, Ai
    Lai, Wei-Chu Victoria
    Arbour, Kathryn Cecilia
    Daras, Mariza
    Pentsova, Elena
    DeAngelis, Lisa Marie
    Beal, Kathryn
    Young, Robert J.
    Jordan, Emmet
    Arcila, Maria E.
    Jones, David Randolph
    Isbell, James M.
    Riely, Gregory J.
    Drilon, Alexander E.
    Yu, Helena Alexandra
    Li, Bob T.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [49] Vimentin expression status is a potential biomarker for brain metastasis development in EGFR-mutant NSCLC patients
    Teocharoen, Rattanawadee
    Ruangritchankul, Komkrit
    Vinayanuwattikun, Chanida
    Sriuranpong, Virote
    Sitthideatphaiboon, Piyada
    [J]. TRANSLATIONAL LUNG CANCER RESEARCH, 2021, 10 (02) : 790 - +
  • [50] Brain metastasis, EGFR mutation subtype and generation of EGFR-TKI jointly influence the treatment outcome of patient with EGFR-mutant NSCLC
    Ju J.-S.
    Huang A.C.-C.
    Tung P.-H.
    Huang C.-H.
    Chiu T.-H.
    Wang C.-C.
    Ko H.-W.
    Chung F.-T.
    Hsu P.-C.
    Fang Y.-F.
    Guo Y.-K.
    Kuo C.-H.S.
    Yang C.-T.
    [J]. Scientific Reports, 13 (1)
12345